CR059 / PegBio - LARVOL DELTA

Single-dose CR059, a circular RNA-encoded GLP-1 analogue, enables sustained exposure and prolonged body weight reduction in non-human primates (EASD 2026) - "Materials and Male healthy rhesus monkeys (n=2/group, baseline body weight ~7-8 kg) received single subcutaneous doses of CR059 (180 or 540 µg/kg) or reference exenatide (Byetta, 0.6 µg/kg, twice daily for 5 weeks). Single-dose CR059 demonstrates rapid and robust body weight-lowering activity in rhesus monkeys, with clear dose- dependent effects and sustained plasma GLP-1RA exposure. Its long-acting profile allows for monthly dosing, potentially reducing gastrointestinal side effects such as nausea and vomiting, and supporting continuous therapy as an alternative or follow-up to existing GLP-1RAs. Together, the PK, PD, and ddPCR data highlight CR059's potential as a durable circRNA-based GLP-1 therapy for weight management and other metabolic diseases."

Circular RNA • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus